Finding new ways to block a key protein involved in leukemia treatment.
Cell-Based HTS Campaign to Identify Negative Allosteric Modulators of the Leukemia-associated Tyrosine Kinase, BTK”.
['FUNDING_R01'] · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · NIH-11059347
This study is looking for new ways to block a protein called BTK that helps B cells grow, which can be a problem in leukemia, especially for patients who haven't responded to current treatments like Ibrutinib, with the hope of finding better and safer options for those battling B cell cancers.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PITTSBURGH AT PITTSBURGH (nih funded) |
| Locations | 1 site (PITTSBURGH, UNITED STATES) |
| Trial ID | NIH-11059347 on ClinicalTrials.gov |
What this research studies
This research focuses on Bruton’s tyrosine kinase (BTK), a protein crucial for the development of B cells, which are often implicated in leukemia. The study aims to identify negative allosteric modulators that can effectively inhibit BTK, especially in cases where patients have developed resistance to existing treatments like Ibrutinib. By utilizing advanced assays and screening techniques, the researchers will explore how to overcome drug resistance and improve treatment outcomes for patients with B cell malignancies. This could lead to the development of new therapies that are more effective and have fewer side effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with B cell malignancies, particularly those who have shown resistance to existing BTK inhibitors.
Not a fit: Patients with B cell malignancies who have not been treated with BTK inhibitors or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with B cell malignancies who have developed resistance to current therapies.
How similar studies have performed: Previous research has shown promise in targeting BTK and overcoming drug resistance, indicating that this approach could be a meaningful advancement in treatment.
Where this research is happening
PITTSBURGH, UNITED STATES
- UNIVERSITY OF PITTSBURGH AT PITTSBURGH — PITTSBURGH, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JOHNSTON, PAUL A. — UNIVERSITY OF PITTSBURGH AT PITTSBURGH
- Study coordinator: JOHNSTON, PAUL A.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.